The University of Southampton
University of Southampton Institutional Repository

Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-hodgkin’s lymphoma

Record type: Article

Purpose: This study was undertaken to test the hypothesis
that serum selenium concentration at presentation correlates with dose delivery, first treatment response, and overall survival in patients with aggressive B-cell non-Hodgkin’s lymphoma.

Patients and Methods: The patients presented between July 1986 and March 1999 and received anthracyclinebased chemotherapy, radiotherapy, or both. The total selenium content was retrospectively analyzed in 100 sera, frozen at presentation, using inductively coupled plasma mass spectrometry.

Results: The serum selenium concentration ranged from 0.33 to 1.51 mol/L (mean, 0.92 mol/L; United Kingdom adult reference range, 1.07 to 1.88 mol/L). Serum selenium concentration correlated closely with performance status but with no other clinical variable. Multivariate analysis revealed that increased dose delivery, summarized by an area under the curve, correlated positively with younger age (P < .001), advanced stage (P .001), and higher serum selenium concentration (P .032). Selenium level also correlated positively with response (odds ratio, 0.62; 95% confidence interval [CI], 0.43 to 0.90; P .011) and achievement of long-term remission after first treatment (log-rank test, 4.38; P .036). On multivariate analysis, selenium concentration was positively predictive of overall survival (hazard ratio [HR], 0.76 for 0.2 mol/L increase; 95% CI, 0.60 to 0.95; P .018), whereas age indicated negative borderline significance (HR, 1.09; 95% CI, 0.99 to 1.18; P .066).

Conclusion: Serum selenium concentration at presentation is a prognostic factor, predicting positively for dose delivery, treatment response, and long-term survival in aggressive non-Hodgkin’s lymphoma. Unlike most existing prognostic factors in aggressive non-Hodgkin’s lymphoma, selenium supplementation may offer a novel therapeutic strategy in this frequently curable malignancy.

Full text not available from this repository.

Citation

Last, Kim W., Cornelius, V., Delves, Trevor, Sieniawska, Christine, Fitzgibbon, Jude, Norton, Andrew, Amess, John, Wilson, Andy, Rohatiner, Ama J.S. and Lister, T. Andrew (2003) Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-hodgkin’s lymphoma Journal of Clinical Oncology, 21, (12), pp. 2335-2341. (doi:10.1200/JCO.2003.06.145).

More information

Published date: 15 June 2003

Identifiers

Local EPrints ID: 162323
URI: http://eprints.soton.ac.uk/id/eprint/162323
ISSN: 1527-7755
PURE UUID: 5d0fd91a-13a2-482a-bd85-e2ccd16d0762

Catalogue record

Date deposited: 18 Aug 2010 13:03
Last modified: 18 Jul 2017 12:32

Export record

Altmetrics

Contributors

Author: Kim W. Last
Author: V. Cornelius
Author: Trevor Delves
Author: Christine Sieniawska
Author: Jude Fitzgibbon
Author: Andrew Norton
Author: John Amess
Author: Andy Wilson
Author: Ama J.S. Rohatiner
Author: T. Andrew Lister

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×